Search research articles
Contact Us
Filters
Showing results (31-40 of 87) with videos related to
Page
of 9
Sort By:
Diabetes Care
|
April 16, 2009
Treatment with the human once-weekly glucagon-like peptide-1 analog taspoglutide in combination with metformin improves glycemic control and lowers body weight in patients with type 2 diabetes inadequately controlled with metformin alone: a double-blind placebo-controlled study
Michael A Nauck, Robert E Ratner, Christoph Kapitza, et al.
Diabetes, Obesity & Metabolism
|
June 16, 2025
Sustained metabolic improvements in a remotely delivered ketogenic nutrition programme for veterans with type 2 diabetes: A 3-year observational study
Rebecca N Adams, Shaminie J Athinarayanan, Alison R Zoller, et al.
Hawai'I Journal of Medicine & Public Health : a Journal of Asia Pacific Medicine & Public Health
|
December 24, 2014
Association of modifiable risk factors and left ventricular ejection fraction among hospitalized Native Hawaiians and Pacific Islanders with heart failure
Marjorie K L M Mau, Todd B Seto, Joseph K Kaholokula, et al.
Diabetes Care
|
April 28, 2005
Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes
Ralph A DeFronzo, Robert E Ratner, Jenny Han, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
November 15, 2005
Impact of computer-generated personalized goals on cholesterol lowering
Claresa S Levetan, Karen R Dawn, James F Murray, et al.
Diabetes Care
|
August 2, 2012
Skin intrinsic fluorescence is associated with coronary artery disease in individuals with long duration of type 1 diabetes
Baqiyyah N Conway, Vanita R Aroda, John D Maynard, et al.
Diabetes Care
|
February 11, 2011
Skin intrinsic fluorescence correlates with autonomic and distal symmetrical polyneuropathy in individuals with type 1 diabetes
Baqiyyah N Conway, Vanita R Aroda, John D Maynard, et al.
Frontiers in Public Health
|
July 5, 2022
Impact of the COVID-19 Pandemic on the Effectiveness of a Metabolic Health Telemedicine Intervention for Weight Loss: A Propensity Score Matching Analysis
Shaminie J Athinarayanan, Rebecca N Adams, Michelle VanTieghem, et al.
Clinical Therapeutics
|
June 17, 2008
Effect of exenatide on 24-hour blood glucose profile compared with placebo in patients with type 2 diabetes: a randomized, double-blind, two-arm, parallel-group, placebo-controlled, 2-week study
Sherwyn L Schwartz, Robert E Ratner, Dennis D Kim, et al.
Journal of Diabetes and Its Complications
|
March 22, 2014
Beneficial effects of once-daily lixisenatide on overall and postprandial glycemic levels without significant excess of hypoglycemia in type 2 diabetes inadequately controlled on a sulfonylurea with or without metformin (GetGoal-S)
Julio Rosenstock, Markolf Hanefeld, Paramesh Shamanna, et al.
Page
of 9
Search research articles
Search
Showing results (31-40 of 87) with videos related to
Sort By:
Page
of 9
Diabetes Care
|
April 16, 2009
Treatment with the human once-weekly glucagon-like peptide-1 analog taspoglutide in combination with metformin improves glycemic control and lowers body weight in patients with type 2 diabetes inadequately controlled with metformin alone: a double-blind placebo-controlled study
Michael A Nauck, Robert E Ratner, Christoph Kapitza, et al.
Diabetes, Obesity & Metabolism
|
June 16, 2025
Sustained metabolic improvements in a remotely delivered ketogenic nutrition programme for veterans with type 2 diabetes: A 3-year observational study
Rebecca N Adams, Shaminie J Athinarayanan, Alison R Zoller, et al.
Hawai'I Journal of Medicine & Public Health : a Journal of Asia Pacific Medicine & Public Health
|
December 24, 2014
Association of modifiable risk factors and left ventricular ejection fraction among hospitalized Native Hawaiians and Pacific Islanders with heart failure
Marjorie K L M Mau, Todd B Seto, Joseph K Kaholokula, et al.
Diabetes Care
|
April 28, 2005
Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes
Ralph A DeFronzo, Robert E Ratner, Jenny Han, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
November 15, 2005
Impact of computer-generated personalized goals on cholesterol lowering
Claresa S Levetan, Karen R Dawn, James F Murray, et al.
Diabetes Care
|
August 2, 2012
Skin intrinsic fluorescence is associated with coronary artery disease in individuals with long duration of type 1 diabetes
Baqiyyah N Conway, Vanita R Aroda, John D Maynard, et al.
Diabetes Care
|
February 11, 2011
Skin intrinsic fluorescence correlates with autonomic and distal symmetrical polyneuropathy in individuals with type 1 diabetes
Baqiyyah N Conway, Vanita R Aroda, John D Maynard, et al.
Frontiers in Public Health
|
July 5, 2022
Impact of the COVID-19 Pandemic on the Effectiveness of a Metabolic Health Telemedicine Intervention for Weight Loss: A Propensity Score Matching Analysis
Shaminie J Athinarayanan, Rebecca N Adams, Michelle VanTieghem, et al.
Clinical Therapeutics
|
June 17, 2008
Effect of exenatide on 24-hour blood glucose profile compared with placebo in patients with type 2 diabetes: a randomized, double-blind, two-arm, parallel-group, placebo-controlled, 2-week study
Sherwyn L Schwartz, Robert E Ratner, Dennis D Kim, et al.
Journal of Diabetes and Its Complications
|
March 22, 2014
Beneficial effects of once-daily lixisenatide on overall and postprandial glycemic levels without significant excess of hypoglycemia in type 2 diabetes inadequately controlled on a sulfonylurea with or without metformin (GetGoal-S)
Julio Rosenstock, Markolf Hanefeld, Paramesh Shamanna, et al.
Page
of 9